LITTLE KNOWN FACTS ABOUT SEVITERONEL BREAST CANCER.

-mutated tumors. Having said that, only a fraction of those people responds to immune checkpoint or PARP inhibitors and in some cases those that do reply often acquire resistance and relapse.Differential effects on AR and AR targets with enzalutamide and seviteronel therapy. AR+ TNBC cells were addressed with 5 μM enzalutamide or seviteronel ± te